Effect of lutein on lipid profile in hypercholesterolemic rats

Uma Narayanamurthy, Anandhi M., Manimekalai K.


Background: Hyperlipidemia or Dyslipidemia is the major cause of atherosclerosis1 and associated conditions. Low levels of high-density-lipoprotein cholesterol (HDL-C) are the major causes of increased atherogenic risk 1. Aggressive cholesterol reduction in patients with atherosclerotic disease is now the standard of care2. In addition to life style modification, patients with risk factors need lipid lowering drug therapy. The drugs available now do not reduce LDL oxidation, and oxidative stress associated with hyperlipidemia. In recent years, antioxidants have been subjected to epidemiological studies4 that have related their consumption to a reduction in the incidence of oxidative damage related diseases.

Methods: Hypercholesterolemia was induced in rats by administration of high cholesterol diet for 30 days in standard rat chow diet. Rats were divided into four groups of six each. Group-I and II with intake of normal diet and High cholesterol diet respectively. Group III and IV are given high cholesterol diet along with Lutein 50mg/kg and Atorvastatin 5mg/kg orally once daily respectively. At the end of 30 days animals were subjected to overnight fasting. Blood samples were drawn by retro-orbital puncture for biochemical analysis. The animals were sacrificed after thiopentone injection and liver and aorta were dissected out and processed for histopathological study and biochemical analysis.

Results: Lutein treated group showed even more significant reduction in TBARS levels than the normal control group and Atorvastatin treated group. The efficacy of Lutein in slowing down the atherosclerosis and fatty infiltration of liver is proved in this study.

Conclusions: Hence the present study had shown significant hypolipidemic, antiatherogenic and antioxidant effect of Luetin in Hyperlipidemic rats.



Aorta, Hyperlipidemia, Liver, Lutein, Oxidative stress

Full Text:



Thomas P. Bersot. Drug Therapy for Hypercholesterolemia and Dyslipidemia. In Goodman and Gilman’s - The Pharmacological Basis of Therapeutics. Eds Laurence LB, Bruce AC, Bjorn CK, 12th Edn. McGraw-Hill Book Co. Newyork; 2011:31:877.

Smith SC, Blair SN, Criqui MH, Fletcher GF, Fuster V, Gersh BJ, et al. Preventing heart attack and death in patients with coronary disease. Journal of the American College of Cardiology. 1995 Jul;26(1).

Kannel WB, Schatzkin A. Sudden death: lessons from subsets in population studies. Journal of the American College of Cardiology. 1985 Jun;5(1):141B-9B.

Rajagopalan. A Review on the Ancient and Modern Views Regarding Medo Parinama Vikriti. Ancient science of life. 1989;9:1.

Mahley RW, Bersot TP. Drug therapy for hypercholesterolemia and dyslipidemia. Goodman & Gilman’s the pharmacological basis of therapeutics. 10th Ed. New York: McGraw Hill; 2001:971-1002.

Gate L, Paul J, Ba GN, Tew KD, Tapiero H. Oxidative stress induced in pathologies: the role of antioxidants. Biomedicine & Pharmacotherapy. 1999 May 1;53(4):169-80.

Tomeo AC, Geller M, Watkins TR, Gapor A. Antioxidant effects of tocotrienols in patients with hyperlipidemia and carotid stenosis. Journal of lipids. 1995;30(12):1179-83.

Engler MM, Engler MB, Malloy MJ, Chiu EY, Schloetter MC, Paul SM, et al. Antioxidant vitamins C and E improve endothelial function in children with hyperlipidemia: Endothelial Assessment of Risk from Lipids in Youth (EARLY) Trial. Circulation. 2003 Sep 2;108(9):1059-63.

Qiu X, Gao DH, Xiang X, Xiong YF, Zhu TS, Liu LG, et al. Ameliorative effects of lutein on non-alcoholic fatty liver disease in rats. World Journal of Gastroenterology: WJG. 2015 Jul 14;21(26):8061.

Priyadharshini SK, Nirmala P, Kumar A. Effect of Lutein in Hypercholesterolemia induced Oxidative Stress in Male Wistar Rats. Int J Curr Pharm Res. 2015;7(2):97-100.

Parek AC, Jung DH. Cholesterol determination with Ferric acetate-Uranium acetate and Sulphuric acid- Ferrous Sulphate reagents. Anal Chem. 1970;42:423-8.

Foster JB, Dunn RT. Stable reagents for determination of serum triglyceride by colorimetric condensation method. Clin Chim Acta. 1973;19:338-40.

Warnick GR, Albers JJ. A comprehensive evaluation of the heparin-manganese precipitation procedure for estimating high density lipoprotein cholesterol. Journal of Lipid Research. 1978 Jan 1;19(1):65-76.

Yagi K. Lipid peroxides and human disease. Chem Physiol Lip. 1978;45:337-57.

Moghadasian MH, Frohlich JJ, McManus BM. Advances in experimental dyslipidemia and atherosclerosis. Laboratory Investigation. 2001 Sep;81(9):1173.

Pramart NS, Shiv P. Antiatherosclerosis/Anti-Hyperlipedemic Activity. In Screening Methods in Pharmacology. Narosa Publishing House. India. 2006;14:297-304.

Vogel GH. Anti-Atherosclerotic activity. In Drug Discovery and Evaluation. 3rd Edn. 2008;14:1661-717.

Pandya N, Santani D, Jain S. Antioxidant activity of Ezetimibe in hypercholesterolemic rats. Indian J Pharmacol. 2006;38:205-6.

Araujo FB, Barbosa DS, Hsin CY. Evaluation of oxidative stress in patients with hyperlipidemia. PMID. 1995;117(1):61-71.

Stein JH, Keevil JG, Wiebe DA, Aeschlimann S, Folts JD. Purple grape juice improves endothelial function and reduces the susceptibility of LDL cholesterol to oxidation in patients with coronary artery disease. Circulation. 1999 Sep 7;100(10):1050-5.

Kita T, Nagano Y, Yokode M, Ishii K, Kume N, Ooshima A, et al. Probucol prevents the progression of atherosclerosis in Watanabe heritable hyperlipidemic rabbit, an animal model for familial hypercholesterolemia. Proceedings of the National Academy of Sciences. 1987 Aug 1;84(16):5928-31.